Navigating the Unknown

Video thumbnail of navigating the unknown

Navigating the Unknown

Listen to actual HUMIRA-treated patients describe the impact of HS, and watch HS-treating dermatologists discuss why they choose HUMIRA for moderate to severe HS

For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older

Explore HiSCR: A clinically meaningful measure of response in HS

HUMIRA is the only FDA approved treatment for hidradenitis suppurativa.

HiSCR: A MEASURE OF CLINICAL RESPONSE IN HS2

At Week 12, many moderate to severe adult HS patients treated with HUMIRA achieved clinically meaningful improvement, defined as Hidradenitis Suppurativa Clinical Response, or HiSCR, vs placebo.1,3

HUMIRA is the only FDA approved treatment for hidradenitis suppurativa.

HiSCR REQUIRES THE FOLLOWING RELATIVE TO BASELINE1,3

50% REDUCTION

in total abscess and inflammatory nodule (AN) count

+

NO INCREASE

in abscess count and draining tunnel count

STUDY DESIGN INTRO

PIONEER I (N=307) and II (N=326) were randomized, double-blind, placebo-controlled clinical trials in adult patients with moderate to severe HS receiving HUMIRA 40 mg weekly (after initial doses). Primary endpoint: HiSCR at week 12 (Period A), defined as ≥50% reduction from baseline in abscess and inflammatory nodule count, with no increase in abscess and draining tunnel counts.1,2